Blog dedicated to the continuous education in Gynecology and Endocrinology

 

Tri-pronucleated zygotes may occur less frequently in LH activity-added cycles

DGYE-2010-0089.R1 [501878] 6 pag

Original Paper
Ku, Seung-Yup (contact); Kim, Yong Jin; Jee, Byung Chul; Suh, Chang Suk; Kim, Seok Hyun; Choi, Young Min; Kim, Jung Gu; Moon, Shin Yong

Objective: This study was performed to evaluate the association between adding LH activity and the incidence of tripronuclear (3PN) zygotes occurrence.
Methods: The incidence of 3PN and cycle outcomes was compared between recombinant FSH (rFSH)-only and rFSH with exogenous LH activity groups. These comparisons were performed in GnRH agonist (GnRHa, n=196) and antagonist (GnRHant, n=182) subgroups, and in IVF (n=243) and ICSI (n=135) cycles, respectively. more

Post to Twitter Post to Facebook

Why does oestrogen-only hormone therapy have such a small impact on breast cancer risk? A Hypothesis.

DGYE-2010-0090[488778]

Eden, John

There seems be irrefutable evidence that oestrogen is involved in the pathogenesis of breast cancer. The disease mostly affects women and the epidemiology of breast cancer relates to reproductive markers such as pregnancy, age at menarche and age of menopause. Most breast cancers elaborate oestrogen receptors (ER) and in such cases endocrine therapies such as tamoxifen and aromatase-inhibitors (AIs) are effective adjuvant treatments. more

Post to Twitter Post to Facebook

Gynecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy

Gadducci, Angiolo, Biglia, Nicoletta; Cosio, Stefania; Sismondi, Piero; Genazzani, Andrea – DGYE-2010-0002[487609]

BRCA1 and BRCA2 mutation carriers have a 54-85% and 45% lifetime risk of developing breast cancer, respectively, and a 18-60% and 11-27% lifetime risk of developing ovarian cancer, respectively. Oral contraceptive [OC]s significantly reduce the risk of ovarian cancer also in BRCA1/BRCA2 mutation carriers. more

Post to Twitter Post to Facebook

Breastfeeding and Basal Insulin Requirement in Type 1 Diabetic Women

powered by WordPress Multibox Plugin v1.3.5


Breastfeeding and Basal Insulin Requirement in Type 1 Diabetic Women
Riviello C

(14th World Congress of Gynecological Endocrinology – March 4-7 2010)

Post to Twitter Post to Facebook

Symposia – Effects of Drospirenone on Breast Tissue

powered by WordPress Multibox Plugin v1.3.5


Effects of Drospirenone on Breast Tissue
Otto Christiane

Post to Twitter Post to Facebook

© International Society of Gynecological Endocrinology - Privacy Policy